ARRY vs INOD

ARRY's deterministic health scores signal significant distress: the Piotroski F-Score of 2/9 indicates poor financial health, with weak profitability, declining revenue, and high leverage. The absence of an Altman Z-Score raises concern, as the Debt/Equity ratio of 2.94 and negative ROE (-19.02%) suggest elevated bankruptcy risk. Despite a modest Price/Sales of 0.82 and a forward P/E of 7.86, the company's -17.9% YoY revenue decline and negative profit margins undermine valuation appeal. Analysts recommend 'buy' with a $10.07 target, but this optimism appears disconnected from deteriorating fundamentals. The 52-week price range ($3.76–$12.23) and recent 1M drop of 37.6% reflect high volatility and weak market confidence.

INOD presents a stark contrast between a clean balance sheet and severe valuation and technical deterioration. With a Piotroski F-Score of 4/9 (Stable) and a Graham Number of $8.28, the stock is trading at a massive premium to its deterministic fair value. While the company maintains a very low debt-to-equity ratio (0.04) and strong ROE (37.76%), these are offset by negative earnings growth (-19.4% YoY) and a catastrophic 6-month price decline of 57.3%. The disconnect between the analyst target price ($91.25) and the current price action suggests a significant market correction is underway.